Endometrial cancer: more than half of patients do not receive guideline-concordant treatment

  • Dholakia J & et al.
  • Gynec Oncol
  • 23 Mar 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • 43.8% of patients with nonendometrioid endometrial cancer do not receive guideline-concordant treatment.
  • Guideline-recommended treatment is associated with improved OS in patients of all ethnicities except Asian/Pacific Islander.

Why this matters

  • Guideline-concordant treatment adherence interventions may improve survival, and barriers to adherence should be identified and addressed.

Study design

  • Study of 30,426 women with nonendometrioid endometrial cancer during 2004-2014.
  • Year-specific National Comprehensive Cancer Network guidelines were used to classify treatment.
  • Funding: National Cancer Institute.

Key results

  • 43.8% of women received guideline-concordant treatment.
  • Guideline-concordant treatment did not differ with race/ethnicity (P=.46).
  • Guideline-concordant treatment was associated with improved OS (HR, 0.85; 95% CI, 0.82-0.87):
    • Non-Hispanic whites (n=21,177): HR, 0.84 (95% CI, 0.80-0.87).
    • Non-Hispanic blacks (n=6657): HR, 0.85 (95% CI, 0.80-0.91).
    • Hispanic (n=1689): HR, 0.84 (95% CI, 0.72-0.98).
  • Survival advantage was not reported in Asian/Pacific Islander patients (n=903) with guideline-concordant treatment.

Limitations

  • Observational study.